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The Epstein–Barr virus (EBV) is a DNA lymphotropic herpesvirus and the causative agent 
of infectious mononucleosis. EBV is highly prevalent since it affects more than 90% of 
individuals worldwide and has been linked to several malignancies including PTLDs, 
which are one of the most common malignancies following transplantation. Among all the 
EBV genes, most of the recent investigations focused on studying the LMP-1 oncogene 
because of its high degree of polymorphism and association with tumorigenic activity. 
There are two main EBV genotypes, Type 1 and 2, distinguished by the differences 
in the EBNA-2 gene. Further sub genotyping can be characterized by analyzing the 
LMP-1 gene variation. The virus primarily transmits through oral secretions and persists 
as a latent infection in human B-cells. However, it can be transmitted through organ 
transplantations and blood transfusions. In addition, symptoms of EBV infection are not 
distinguishable from other viral infections, and therefore, it remains questionable whether 
there is a need to screen for EBV prior to blood transfusion. Although the process of 
leukoreduction decreases the viral copies present in the leukocytes, it does not elimi-
nate the risk of EBV transmission through blood products. Here, we provide a review 
of the EBV epidemiology and the genetic variability of the oncogene LMP-1. Then, we 
underscore the findings of recent EBV seroprevalence and viremia studies among blood 
donors as a highly prevalent transfusion transmissible oncovirus.
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iNTRODUCTiON
The Epstein–Barr Virus (EBV), also called human herpesvirus 4, is a lymphotropic herpesvirus and 
the causative agent of infectious mononucleosis (IM) (1). It was first discovered in cells isolated 
from African Burkitt’s lymphoma, later, it was recognized that it is highly prevalent worldwide (2). 
Similar to other herpesviruses, following a primary infection, the EBV has a latency phase where it 
infects epithelial cells, enters the circulating B lymphocyte, and persists for the life in a latent state 
(3). According to epidemiological studies, the EBV is estimated to be positive in more than 90% 
of the world’s populations (4). Typically, the primary infection is asymptomatic and occurs during 
childhood. However, the infection could lead to IM if it occurs in adults (5). In addition, this virus 
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has been linked to a wide range of malignancies, such posttrans-
plant lymphoproliferative diseases (PTLDs), nasopharyngeal 
carcinoma (NPC), Hodgkin’s lymphoma, and gastric carcinoma 
(MS) (4–8).
The oral route is the primary route of the EBV transmission. 
However, it has been reported that organ transplantation and 
blood transfusion can lead to EBV spread (9–11). Through the 
screening for numerous infectious pathogens, blood banking 
services spend intense efforts and follow strict precautions 
to minimize the risk of EBV transmission in transfusion. 
Nonetheless, concerns regarding the transmission of untested 
pathogens, such as HEV (12), CMV (13), and EBV (14), are still 
present. Indeed, blood banks rely on leukoreduction to minimize 
the number of EBV genome and confirm the safety of blood 
products. However, it was found that leukoreduction does not 
eliminate the risk of EBV transmission since the virus can still 
be detected in leukoreduced blood products (14). Therefore, 
blood products are considered still potentially dangerous for 
recipients of blood transfusion, in particular, high-risk individual 
including organ transplanted and immunocompromised patients 
(14, 15). However, most EBV studies focus on serological assays 
(14, 16–19), and limited number of studies have investigated the 
EBV viremia in healthy blood donors (20–23).
There are two main EBV genotypes, type 1 and type 2, or A 
and B, respectively, distinguished by the differences in EBNA-2 
gene, since the divergence in EBNA-2 reveals only 54% homology 
between the two types (24). EBV types 1 and 2 can further be 
subdivided into different virus strains (25). Most of the investiga-
tions concerning the genetic variability of EBV strains were based 
on studying the LMP-1 oncogene since it has a greater degree of 
polymorphism than most of the others EBV genes (26). Variants 
in LMP-1 were classified into 7 main groups: B95-8, Alaskan, 
China 1, China 2, Med+, Med−, and NC (4, 6, 27). However, 
new LMP-1 strains were reported from different origins such as 
the Southeastern Asia 1 (SEA1), and Southeastern Asia 2 (SEA2) 
reported in Thailand (28, 29). Interestingly, it was found that 
multiple EBV variants could be detected within one individual 
(25). Moreover, some LMP-1 variants were correlated with cancer 
progression such as CAO strain, which was isolated from NPC 
patient is China and has shown to carry atypical 10 amino acid 
deletion resulted in increased transforming ability (27).
This paper provides insights about EBV in healthy blood 
donors by reviewing recent reports about the virus epidemiology, 
serology, and detection, in addition to the genetic variability of 
LMP-1 oncogene.
eBv STRUCTURe AND GeNOMe
The EBV virion structure is similar to other herpesviruses. It 
consists of a toroid-shaped protein core wrapped with the viral 
DNA inside an icosahedral capsid of 162 capsomers, a viral 
tegument containing a protein that lines the space between the 
nucleocapsid, and the outer envelope, with different glycoprotein 
spikes inserted into the viral envelop (6, 30).
The EBV genome is composed of a linear, double-stranded 
DNA with a relatively large genome size of ~ 172 kilobase pairs 
(kbp) that encodes for more than 85 genes (5, 6). In order to 
have the highest coding capacity, the viral genome is divided into 
short and long unique sequence domains, which are formed by a 
series of around 540-bp terminal direct repeats and around 3.1-
kbp large internal repeats (31, 32). These repetitions serve as an 
indicator to determine whether the source of EBV in the infected 
cells comes from the same progenitor cell (6). The nomenclature 
of the EBV open reading frames was established according to a 
BamHI-restriction fragments map, where the found fragments 
were ordered in descending order from A to Z based on their 
sizes. The fragments were also divided into latent or lyric genes 
(6, 30).
Most of the proteins encoded by the EBV genome are involved 
in the nucleotides metabolism, to maintain the replication of the 
viral DNA, and to build the structural compartments of the virus 
such as the nucleocapsid, tegument proteins, and the envelope 
(31). Additionally, the EBV genome consists of several latent 
genes that are non-translated during the lytic phase, along with 
a number of latency associated RNA genes that are expressed 
during latency (6, 31). During a latent EBV infection, the viral 
genome persists for life-long in multiple circular episomes inside 
the infected cell nucleus. During the cell division, in order to 
maintain this episome like plasmids, two components are needed: 
a cis-acting DNA segment (oriP), and a trans-acting nuclear 
protein (33). In latency, only a few viral genes are expressed, 
which includes the six EBV nuclear proteins: EBNA-1, EBNA-
2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-LP, in addition to 
three latent membrane proteins: LMP-1, LMP-2A, LMP-2B (5). 
Furthermore, although the EBV DNA usually persists in the 
form of episome, it was found that it can integrate into the cell 
chromosomal DNA, and persist as integrated DNA as well (34).
eBv GeNOTYPeS AND STRAiN 
vARiATiON
It has long been known that there are two different EBV genotypes: 
Type 1 and Type 2, also known as Type A and B, respectively (32). 
These two genotypes were distinguished based on the differences 
in the EBNA-2 gene since the EBNA-2 clearly classifies Type 1 and 
Type 2, where the rest of the EBV genes differ only by less than 
5% in their sequence (4, 6). The EBNA-3 gene family also shows 
variations between the EBV genotypes, but with less degree of 
sequence difference than the EBNA-2 gene (4). The divergence 
in EBNA-2 reveals only 54% of homology between the two 
types, facilitating the distinction between each EBV type (24). 
Interestingly, it was found that the EBV types noticeably differ in 
their transformation abilities. For instance, the EBV Type 1 trans-
forms the B lymphocytes more willingly than Type 2 in vitro, and 
when a recombinant Type 2 virus acquired the Type 1 EBNA-2A 
gene, it gained the transforming ability of Type 1 virus (35).
Epstein–Barr virus Type 1 and 2 can further be subtyped into 
different EBV strains (25). The genetic variability between the 
different EBV strains is thought to occur due to the nature of 
the EBV life cycle within the lymphocytes. For instance, when 
the EBV infected lymphocyte passes through the germinal center 
of the lymph node, which is considered a highly mutagenic envi-
ronment, and thus a location were an increased rate of mutations 
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could occur (36). Consequently, the EBV can induce errors 
during replication and creates more genetic variability between 
individuals (36). There are many studies in the literature focusing 
on investigating the genetic variability of the EBV strains trying 
to correlate this variability to the geographic areas and the disease 
outcomes (5). In these studies, genes which were identified to have 
an important role in the EBV viral life cycle were sequenced, such 
as BZLF1, EBNA-1, EBNA-2, EBNA-3A, -3B, and -3C, LMP-1, 
and LMP-2a (28, 37–40).
Interestingly, among the proteins involved in the EBV viral 
life cycle, LMP-1 is the only protein with oncogenic properties 
as indicated by its ability to transform rodent fibroblasts and 
establish tumor cells (41–43). Indeed, a recombinant virus 
lacking LMP-1 was reported unable to immortalize resting B 
lymphocytes (44). Many reports indicated that LMP-1 is not only 
essential for the outgrowth of lymphoblastic cells but also for the 
survival and proliferation of these cells (45). The oncogenic ability 
of LMP-1 can be attributed to its effect on a plethora of functional 
activities including DNA synthesis, suppression of cell senes-
cence, production of cytokines (IL-6, -8, and -10), upregulation 
of anti-apoptotic proteins (Bcl-2, Mcl-1, Bfl-1, A20, and cIAPs) 
and cell surface markers (CD23, CD40 ICAM1, LAF1 and LFA3), 
and epithelial growth factor receptor (41, 46, 47). Furthermore, it 
has also been shown that LMP-1 is able to induce the activation 
and secretion of different matrix metalloproteinases suggesting 
an important role for this oncoprotein in both the angiogenic 
and metastatic process during the onset and development of 
EBV-associated tumors (48). Noteworthy is the observation that 
LMP-1 expression, and in turn all the biological and function 
effects related to it, can be induced by circulating’s cytokines, a 
phenomenon that may explain the heterogeneous expression of 
this viral oncogene both in normal and malignant cells (49).
THe LMP-1 ONCOGeNe vARiATiON
Most of the recent investigations on the EBV strain variation were 
based on studying the LMP-1 oncogene sequence, because it has 
shown to have a greater degree of polymorphism than most of 
EBV genes between different strains (4). LMP-1 is a 356-amino 
acid protein, which consists of a short cytoplasmic N-terminus, six 
membrane-spanning domains, and a long cytoplasmic C-terminal 
domain (26). The cellular signaling pathways targeted by LMP-1 
share functional characteristics with members of the tumor 
necrosis factor (TNF) receptor superfamily. Molecular studies 
have revealed that the C-terminal domains (CTAR1 and CTAR2) 
of LMP-1 play an important role in signal transduction through 
mimicking the CD40-mediated signaling (50). The LMP-1 pro-
tein binds the tumor necrosis factor receptor-associated factor 
(TRAF) proteins and the TNF receptor-associated death domain 
protein (TRADD) activating several intracellular pathways 
including NF-κB, the mitogen-activated protein kinases JNK and 
p38, the small GTPase Cdc42, and the JAK/AP-1/STAT cascades. 
Activation of these intracellular signaling cascades enhances cell 
survival and proliferation and may account for many of the cel-
lular changes observed in response to LMP-1 (50–52). Moreover, 
the LPM1 protein works as homologous to the TNF-receptor 
family in the B lymphocytes and epithelial cells (6). Therefore, 
when the LMP-1 protein is mutated, sequence variation can affect 
cell process directly as it interferes with major cellular signaling 
pathways (4). It is well known now that LMP-1 is essential in the 
transformation of B lymphocytes into a lymphoblastoid cell line, 
and it has the ability to block apoptosis by upregulating different 
anti-apoptotic proteins such as A20 and Bcl-2 and inhibiting the 
p53-mediated apoptosis (6) (Figure 1).
Based on the LMP-1 sequence variation, the EBV strains were 
classified into seven main groups/variants relative to the wild-
type strain B95-8. The nomenclature of these variants reflects 
their geographic origin or the location from where they were 
found: Alaskan (Ala), China (Ch1) and (Ch2), Mediterranean 
(Med+) and (Med−), and North Carolina (NC) (4, 27). However, 
new strains were reported from different origins. In Thailand, two 
other new variants were found which were named: SEA1, and 
SEA2. The Chinese del-LMP-1 (CAO) isoform variant was also 
isolated from NPC patients (11, 12).
Multiple EBV variants can be detected within one individual, 
as a patient can be infected with more than one type (25). There 
is evidence of specific multiple LMP-1 variants found in people 
infected with mononucleosis, EBV-associated malignancies such 
as Hodgkin Lymphoma and NPC, as well as in human immu-
nodeficiency virus (HIV) patients (4). Interest in LMP-1 variants 
has increased when findings correlating LMP-1 variants with 
specific cancers were reported. For instance, a variant with 30-bp 
deletion was frequently detected in NPC patients, and this variant 
showed higher transforming activity than the typical LMP-1 (53). 
Furthermore, a 69-bp deletion variant has also been reported in 
Burkitt’s lymphoma and at a lesser rate also in NPC. Additionally, 
the 69 bp deletions were also correlated with a decreased acti-
vation of the AP-1 transcription factor (4, 54). Several reports 
also investigated the presence of LMP-1 variants among healthy 
carriers (20, 25, 55). A recent study compared the prevalence of 
EBV genotypes and del-LMP-1 among Polish, Taiwanese and 
Arabic healthy individuals revealed that 62.5% Taiwanese and 
55.6% Polish had a 30-bp deletion in the LMP-1 gene. However, 
the study reported that this deletion was not present in the Arabs 
population (20). Another study investigated the frequency of 
the 30-bp deletion in EBV healthy carriers from Argentina and 
found that it was present in 28% of these healthy people (55). In 
our study investigating the molecular variability of LMP-1 gene 
in healthy donors, the 30-bp deletion was observed in 30.6% of 
study subjects (23).
eBv viRAL LiFe CYCLe AND ACTivATiON
The EBV usually spreads through the saliva, then it enters the 
epithelium of the tonsils and starts the lytic phase of infection 
that involves virus replication (6) (Figure  2). Infected naive B 
lymphocytes become activated lymphoblasts and migrate to the 
lymph node follicle to initiate a reaction in the germinal center 
of the follicle using the “latency III” program, where all latent 
growth proteins are expressed and adversely regulate the EBV 
growth. Among the virus proteins expressed during this phase 
are the EBV nuclear antigens (EBNA-1, -2, -3, -3A, -3B, -3C, and 
-LP), and latent membrane proteins [LMPs (LMP-1, -2A, and 
-2B)] (6, 56). Type II latency program then is initiated in which 
FiGURe 2 | Epstein–Barr virus (EBV) life cycle in healthy carriers. The infection begins when EBV infect epithelial cells and naïve B cells of the oral cavity. EBV 
genome will be transported to the nucleus of B cell where it will replicate and results in the proliferation of B cells. Latency occurs when EBV downregulate most  
of its protein-encoding genes. Later, as cells recirculate between peripheral and oral compartments, resting B cells will be reactivated and cause viral shedding.
FiGURe 1 | Schematic representation describing the mechanism by which LMP-1 protein affects cell signal transduction. CTAR1 and CTAR2 bind to TRAF proteins 
and activate NF-κB and JNK–AP-1 pathways. LMP-1 can block cell apoptosis signals by activating BCL2A1.
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only EBNA-1, the EBERs, the BARTs, LMP-1, and LMP-2A are 
expressed (56), and survival signals will be provided to cells to 
move out of the germinal center as memory B lymphocytes (6). 
The “Latency 0” phase begins in the memory B lymphocytes, 
and it is characterized by arrest all the viral proteins expression 
(6). If only the EBNA-1 gene is expressed when these memory 
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B lymphocytes divide, then the phase is called “latency type I” 
(33, 57). The infected memory B lymphocytes can also migrate 
back to the tonsils, where they can induce more viral replication 
and spreading and thus infect other B lymphocytes as well (3). 
In the primary infection, T  lymphocytes are responsible for 
eliminating the newly infected cells and controlling the infection. 
However, during latency, the EBV is hidden from the immune 
system as it remains silent in the resting memory B lymphocytes 
without expressing any viral protein (6, 58).
Viral reactivation can occasionally happen in latently infected 
memory B lymphocytes and leads to a new viral cycle, where it 
replicates, infects new cells, and sheds in the saliva (56). Under 
healthy conditions, immunocompetent individuals can have 
EBV reactivation with no specific symptoms due to the infection 
control by the cytotoxic T  lymphocytes (59). However, EBV 
reactivation can be life threatening in patients under immuno-
suppression and can lead to severe EBV-related pathologies, such 
as posttransplant lymphoproliferative disorders (PTLDs) (59). 
There are several described causes of EBV reactivation, including 
the presence of foreign antigen that leads to memory B lympho-
cytes division, which in turn can induce viral reactivation and 
replication (60), meaning that any new infection can lead to EBV 
reactivation (6). For instance, malaria infection has been linked 
to EBV reactivation, as P. falciparum antigens can directly trigger 
EBV reactivation and, therefore, can increase the risk of devel-
oping Burkitt’s lymphoma in malaria endemic areas (61). The 
cystein-rich inter-domain region 1α in the P. falciparum mem-
brane protein 1, was found to activate the memory B lymphocytes 
where the EBV resides (61). Other causes of virus reactivation 
are immunodeficiency and immunosuppression, which are due 
to altered immune system. In this case, uncontrolled reactivation 
of EBV may occur and can lead to various lymphoproliferative 
diseases (59). Other factors, such as inflammation and chemical 
agents or drugs, have also been linked to EBV reactivation from 
latently infected cells (6).
Many studies have been conducted to investigate the EBV 
host cell interactions and the latency associated with the EBV 
infection in different cell types and various medical conditions 
(62). In healthy hosts, B lymphocytes and epithelial cells are the 
cellular targets for EBV primary infection. However, the EBV can 
infect a wide range of non-B lymphocytes, and it critically affects 
the development and pathogenesis of EBV-related diseases (63). 
Early studies reported the presence and replication of EBV viral 
particles in the oropharyngeal epithelial cells of patients with 
acute IM (64, 65), and in epithelial cells of HIV patients suffering 
from oral hairy leukoplakia (66). More recent studies showed that 
the tonsil epithelium of asymptomatic patients has the ability to 
carry EBV infection, which is a part of the viral life cycle (67). 
Furthermore, the EBV can also infect T  lymphocytes, plasma 
cells, NK  cells, monocytes, follicular dendritic cells squamous, 
myoepithelial and glandular epithelial cells, and smooth muscle 
cells (68–72).
Despite the wide range of suspected cell types involved in the 
EBV infection, it appears that B lymphocytes have a critical role 
in the viral life cycle, as agammaglobulinemia patients, who have 
a genetic mutation that leads to the absence of mature B lympho-
cytes, are not affected by EBV (73). Primary B lymphocytes can be 
easily infected with the EBV since B lymphocytes possess a major 
receptor molecule of the virus called cellular complement recep-
tor type 2 (CR2 or CD21), which binds to the EBV glycoprotein 
gp350/220 (56). On the other hand, the interaction of EBV with 
epithelial cells is less understood. It appears that epithelial cells 
acquire the infection through transfer from EBV-coated B lym-
phocytes (62). In vitro studies showed that a low rate of infection 
was achieved when epithelial cells were exposed to cell-free virus 
preparations, while a quantifiable level of infection was reached 
when epithelial cells were cultured with EBV infected B lympho-
cytes. This prompts the idea of the importance of B lymphocytes 
in the infection (74). Moreover, EBV might enter the epithelium 
through the surface of resting B lymphocyte. B lymphocyte can 
act as a shuttle, to transfer the EBV infection to CD21 negative 
epithelial cells after the EBV binds to its surface (74). However, it 
is still in doubt whether B lymphocytes or epithelial cells are the 
primary targets of EBV spread (31).
eBv TRANSMiSSiON AND 
SeROPRevALeNCe
The main route of the EBV transmission is the oral route, as it is 
generally transmitted through the saliva that contains infected 
epithelial cells (75). Also, it can spread through the blood, by 
means of blood transfusion and organ transplantations (1, 9, 11, 
14). Infected epithelial cells can also be found in the uterine cervix 
or in the semen, suggesting the possibility of EBV spread through 
sexual contact (75). Kissing, sharing personal objectives such as 
toothbrushes, eating utensils, or sharing food and drinks with an 
infected individual can all lead to EBV spread (1).
In healthy individuals, the EBV is highly prevalent, as it affects 
more than 90% of individuals worldwide (17). The age of primary 
infection was found to vary according to socioeconomic factors 
that are reflected by crowdedness and low sanitation (6). The EBV 
seroconversion occurrence has two patterns. In developed coun-
tries with high hygiene standards, the EBV seroconversion peaks 
in children between 2 and 4 years and also in 14 and 18 years, 
and it increases with age, ranging from 0 to 70% at childhood 
and reaching to more 90% in adulthood (14). Contrary, in coun-
tries with poor hygiene standards, the EBV infection is usually 
acquired in early childhood, and almost all children in those 
developing countries are seropositive by the age of 6 years (75).
DiSTRiBUTiON OF eBv GeNOTYPeS
Epstein–Barr virus types occur worldwide, but they differ in 
their geographic distribution. For instance, Type 1 is prevalent in 
population from Europe, America, China, and South Asia, while 
Type 2 is less prevalent in these populations and is more observed 
in African and Papua New Guinean populations, where it shares 
an equal distribution with Type 1 (6, 76). Immunocompromised 
patients are more susceptible to acquire both types (6). However, 
healthy individuals as well can have mixed infection with both 
Type 1 and 2 (25). In a recent study conducted on healthy blood 
donors in Qatar (23), we have reported a predominance of the 
genotype 1 (72.5%) as compared to the genotype 2 (3.5%), and 
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mixed infection with both genotypes was detected in 4% of the 
samples. Nonetheless, it is still not known how many EBV vari-
ants can be found in one individual, and whether the immune 
system of a previously infected individual provides protection 
against new multiple variants (36).
eBv iN BLOOD DONATiON AND ORGAN 
TRANSPLANTATiON
It has long been known that blood transfusions and organ trans-
plantations can be routes for EBV transmission, as reported in 
1969 by Gerber et al. (9). In this study, it was shown that patients 
receiving donor blood during an open heart operation acquired 
the EBV infection, indicating the possibility of EBV transmission 
by blood transfusion. Furthermore, early studies revealed that the 
EBV transmission could also occur through organ transplanta-
tion, where patients developed IM after transplantation (10, 11). 
Reports showed that a healthy EBV seropositive individual car-
ries around 0.1–50 EBV infected B lymphocytes per 1,000,000 
peripheral blood mononuclear cells. Therefore, it is possible that 
EBV can be transmitted through the white blood cells of the 
blood (14, 77).
The majority of the epidemiological studies on viral infections 
including EBV were based on serological assays rather than on the 
detection of the EBV viremia (14, 16–19). Nonetheless, measuring 
the amount of circulating viral load can better reflect the infection 
status (78–80). A limited number of studies have investigated the 
EBV viremia in healthy individuals (20–23). A study performed 
in us showed that 72 of a 100 randomly selected blood donors 
had a detectable EBV DNA, suggesting that the potential for 
transfusion-mediated transmission of EBV is high (22). In Japan, 
randomly selected blood donors were tested for the presence of 
EBV DNA and the results showed that the EBV DNA was detected 
in 39.5% of the donors (81). Another recent study in Burkina Faso 
showed a lower level of EBV rate among blood donors, as it was 
detected in only 5.1% of the donors (82). Previous studies from 
Middle Eastern countries, including Saudi Arabia (83), Kuwait 
(84), the UAE (85), Egypt (86), Jordan (87), and Syria (88), have 
studied the association of EBV and multiple diseases such as 
Hodgkin’s lymphoma (reported prevalence of 28–87%), but EBV 
serological and molecular prevalence among healthy individuals 
was not investigated. We have recently studied the rate of EBV 
infection among 673 healthy blood donors from different nation-
alities in Qatar (23), we reported a seroprevalence of 97.9%, and a 
viremia rate of 52.6%, with a viral load ranged between 0.915 and 
2,585.5 copies/ml of blood. Both EBV seroprevalence and viremia 
rates increased significantly with age (23).
The EBV has been linked to the development of posttrans-
plant lymphoproliferative disorders (PTLDs) which is a group 
of heterogeneous diseases that develop in immunocompromised 
patients after receiving a solid organ or hematopoietic stem cell 
transplant (89). The incidence of lymphoproliferative disorders 
increases with solid organ and bone marrow transplantations 
(90, 91). PTLDs develop as a result of immunosuppression, 
and they vary from benign slow polyclonal proliferations to 
overtly malignant monoclonal proliferations of lymphocytes 
and plasma cells (89, 92). PTLD was first reported in 1968 in 
two renal transplantation recipients, and it was linked to the 
immunosuppressive therapy that was administered to the 
patients (93). Mortality from PTLDs is high with no progress in 
the outcomes over the years (94). The World Health Organization 
classifies PTLDs to (i) early lesions of polyclonal or oligoclonal 
lymphoid proliferations that are mainly derived from EBV infec-
tion and (ii) late monoclonal lymphoproliferative diseases that 
are not necessarily associated with EBV, including polymorphic 
and monomorphic PTLDs, which also can be subdivided into 
Burkitt’s lymphoma, Burkitt’s-like lymphoma, diffuse large B-cell 
lymphoma, and Classical Hodgkin Lymphoma (95). It has been 
known that oncogenic herpesviruses like EBV and HHV-8 are 
involved in the development and pathogenesis of PTLDs because 
these viruses have the ability to infect and transform B lympho-
cytes directly (67). Indeed, EBV was found to be present in up 
to two thirds of the PTLD cases (89). A higher risk to develop 
PLTDs is found in EBV negative than in EBV-positive recipients 
regardless the status of the donor, but the highest risk is when 
the recipient is EBV negative, and the donor is EBV positive (96).
Efforts to prevent the transmission of the EBV from EBV-
positive donors rely on the process of leukoreduction, which was 
introduced in 1999, and aimed to remove the white blood cells 
from various blood products (96). In a study of leukoreduction 
efficacy, Qu et al. concluded that EBV PCR negative blood prod-
ucts after leukoreduction, are expected to have a very low prob-
ability of transmissible EBV, and thus the risk is highly reduced 
(97). However, a recent study showed that the EBV was detected 
in one platelets bag after leukoreduction (15). The above finding 
indicates that the leukoreduction does not rule out the possibil-
ity of EBV transmission, and leukoreduced blood products can 
harbor the EBV. Consequently, there might be a potential risk in 
immunocompromised patients who are more vulnerable to EBV 
infection, and patients who receive large volumes of blood (15).
DeTeCTiON OF eBv
The clinical presentation of the EBV infection usually overlaps 
with other acute viral syndromes caused by other viruses such as 
CMV and hepatitis viruses, which can lead to similar symptoms 
(98). The above aspect emphasizes the importance of having 
reliable laboratory diagnostic tools that help in the differential 
diagnosis. Diagnostic schemes of EBV differ according to the 
patient’s immune condition because the importance and urgency 
of therapeutic intervention differ between immunocompromised 
and immunocompetent individuals. A wide range of assays was 
utilized in the diagnosis of EBS. This includes the use of nonspe-
cific tests such as heterophile antibodies detection (mono spot 
test), EBV specific serological assays such as ELISA, EIA, IFA, 
chemoluminescence, immunoblot, and IgG avidity, and molecu-
lar assays for nuclear acid detection (99). Other diagnostic tools 
also have been used in the detection of EBV-associated tumors 
such as immunhistochemistry and immunocytology (99, 100).
SeROLOGiCAL TeSTiNG
Serological testing is based on the detection of EBV antibodies 
in the patient’s serum. Although the serology for EBV diagnosis 
FiGURe 3 | A scheme of serological response to Epstein–Barr virus (EBV) infection. Viral capsid antigens (VCA)-IgM is detected in the active phase of infection and 
then declines in convalescence. VCA-IgG increases at the same time of VCA-IgM, but it remains positive for life indicating past infection. Epstein Barr nuclear 
antigens (EBNA) antibodies are detectable late in the phase of infection and also remain positive. Early antigens (EA) antibodies to the class R or D increase in the 
acute phase of infection and decline after convalescence.
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shows a high degree of variability, it is still preferred and com-
monly used compared other tests, as it provides reasonable criteria 
to identify the patient’s infection status (99). The EBV genome 
codes for different structural and nonstructural genes, some of 
these genes are used in the serological diagnosis, as the humoral 
response produces antibodies against the product of these genes. 
Among the genes used in the test are genes that codes for the viral 
capsid antigens (VCAs), the early antigens (EAs), as well as the 
genes that code for Epstein–Barr nuclear antigens (EBNAs) (98, 
99). The heterophile test is also one of the commonly used tests 
to help in the clinical diagnosis. This test is based on heterophile 
antibodies detection which are antibodies that agglutinate eryth-
rocytes from animal sources and is mainly linked to mononucleo-
sis caused by the EBV infection or infrequently by other diseases 
(101). This test is easy to perform, inexpensive, and commercially 
available, but it lacks specificity, as false-positive results were 
reported in other conditions such as in autoimmune diseases and 
cancers which were found unrelated to the EBV infection (102). 
Moreover, this assay shows low sensitivity with high false nega-
tive results when used for children younger than the age 2 years 
old, as they might lack specific EBV antibodies (101, 103). In 
immunocompetent individuals, usually at least three serologi-
cal parameters are needed to detect EBV antibodies: VCA-IgG, 
VCA-IgM, and EBNA-1 IgG (104). Detection of IgG antibodies 
to EBV EA can also be done and helps in the differentiation of the 
EBV diseases status (99, 101) (Figure 3).
The VCA is a complex of seven structural proteins and 
glycoproteins, and it is synthesized in the lytic cycle of the EBV 
replication (105). The serodiagnosis of VCA is based on the 
detection of antibodies against the two recombinant VCAs: the 
N- terminal of full length p23 and the carboxy half of p18 (106). 
These two proteins were joined in vitro by autologous gene fusion 
in 1999, establishing the bases for developing novel EBV ELISAs 
(106, 107). VCA antibodies detection involves the two immuno-
globulin classes IgG and IgM. The humoral response to the VCA 
complex is typically found early at the onset of clinical symptoms 
(102). In a study investigating EBV status in college students, 
VCA-IgM was detected by enzyme immunoassay 8 days earlier 
than the onset of the symptoms (102). VCA-IgM is produced 
transitionally and used as an indicator of recent primary infec-
tion. Indeed, VCA-IgM is no more detected after convalescence, 
and generally it does not occur another time in life (99). Although 
VCA-IgM appears early and helps in the diagnosis of acute EBV 
infection, some limitations that interfere with the accurate inter-
pretation of the results are present. For example, some children 
and adults might have negative VCA-IgM in primary acute infec-
tion (101), and EBV-IgM cross-reactivity with other antigenically 
related infections especially CMV (108, 109). VCA-IgG is found 
in acute, convalescence, or past infections, as it starts to appear at 
the same time as VCA-IgM (99, 101, 106). Antibodies against the 
p18 components develop after p23 antibodies and then persist for 
life as an indication of EBV exposure (102). Measuring VCA-IgG 
antibodies are found to be a best single test to indicate a previous 
EBV infection as all patients with IM produce IgG antibodies to 
VCA (110).
The EBV nuclear antigen (EBNA) is composed of six proteins 
(EBNA-1, -3, -3A, 3B, 3 C and LP) (3). The EBNA-1 protein is 
expressed in all EBV infected cells, and IgG against this protein 
is a late marker of EBV infection (110). EBNA-1 IgG antibodies 
appear late, 3 to 6  months after the time of disease, then they 
TABLe 1 | Primers used for detection Epstein–Barr virus (EBV) DNA.
Gene/region Method Primers Reference
EBNA-1 gene Nested PCR - Outer primers:
Forward primer: 5′-GTA GAA GGC CAT TTT TCC AC-3′
Reverse primer: 5′-CTC CAT CGT CAA AGC TGC A-3′
- Inner primers:
Forward primer: 5′-AGA TGA CCC AGG AGA AGG CCC AAG C-3′
Reverse primer: 5′-CAA AGG GGA GAC GAC TCA ATG GTG T-5′
(133)
Real-time PCR Forward: 5′-TCATCATCATCCGGGTCTCC-3′
Reverse: 5′-CCTACAGGGTGGAAAAATGGC-3′
Probe: 5-(FAM)-CGCAGGCCCCCTCCAGGTAGAA(TAMRA)-3′
(134)
Forward: 5′-GACTGTGTGCAGCTTTGACGAT-3′
Reverse: 5′-CGGCAGCCCCTTCCA-3′
Probe: 5′-(FAM)-TAGATTTGCCTCCCTGGTTTCCACCTATG-(TAMRA)-3′
(20, 134–136)
BamH1-K Real-time PCR Forward primer: 5′-CCG GTG TGT TCG TAT ATG GAG-3′
Reverse primer: 5′-GGG AGA CGA CTC AAT GGT GTA-3′
Probe: 5′-TGC CCT TGC TAT TCC ACA ATG TCG TCT T-3′ (SEB).
(137)
EBNA-2 Gene Nested PCR - Outer primers:
Forward primer: 5′-AGGGATGCCTGGACACAAGA-3′
Reverse primer: 5′-TGGTGCTGCTGGTGGTGGCAAT-3′
- Inner primers:
EBV type 1
Forward primer: 5′-TCTTGATAGGGATCCGCTAGGATA-3′
Reverse primer: 5′-ACCGTGGTTCTGGACTATCT-GGATC-3′
EBV type 2
Forward primer: 5′-CATGGTAGCCTTAGGACATA-3′
Reverse primer: 5′-AGACTTAGTTGATGCCCTAG-3′
(23)
- Outer primers:
Forward primer: 5′-TTT CAC CAA TAC ATG ACC C-3′
Reverse primer: 5′-TGG CAA AGT GCT GAG AGC AA-3′
- Inner primers:
Forward primer: 5′-CAA TAC ATG AAC CRG AGT CC-3′
Reverse primer: 5′-AAG TGC TGA GAG CAA GGC MC-3′
(20)
- Outer primers:
Forward primer: 5′-TGGAAACCCGTCACTCTC-3′
Reverse primer: 5′-TAATGGCATAGGTGGAATG-3′
- Inner primers:
Forward primer: 5′-AGGGATGCCTGGACACAAGA-3′
Reverse primer: type 1 EBNA-2:5′-GCCTCGGTTGTGACAGAG-3′
type 2 EBNA-2:5′-TTGAAGAGTATGTCCTAAGG-3′
(138)
EBNA-3C Conventional PCR Forward primer: 5′-AGAAGGGGAGCGTGTGTTGT-3′
Reverse primer: 5′-GGCTCGTTTTTGACGTCGGC-3′
(139)
EBNA-5 BamHI-W Fragment Real-time PCR Forward primer: 5′-AGGCTTAGTATACATGCTTCTTGCTTT-3′
Reverse primer: 5′-CCCTGGCTGATGCAACTTG-3′
Probe: 5′-GCAGCCTAATCCCACCCAGACTAGCC-3′
(140)
Forward primer: 5′-CCCAACACTCCACCACACC-3′
Reverse primer: 5′-TCTTAGGAGCTGTCCGAGGG-3
Probe: 5′-(FAM)CACACACTACACACACCCACCCGTCTC-3′
(139, 141)
Conventional PCR Forward primer:5′-CCAGACAGCAGCCAATTGTC-3′
Reverse primer: 5′-TAGAAGACCCCCTCTTAC-3′
(139)
Forward primer: 5′-ACC TGC TAC TCT TCG GAA AC-3′
Reverse primer: 5′-TCT GTC ACA ACC TCA CTG TC-3′
(137, 139)
LMP-1 gene Nested PCR - Outer primers:
Forward primer: 5′-AGTCATAGTAGCTTAGCTGAA-3′
Reverse primer: 5′-CCATGGACAACGACACAGT-3′
- Inner primers:
Forward primer: 5′-AGTCATAGTAGCTTAGCTGAA-3′
Reverse primer: 5′-CAGTGATGAACACCACCACG-3′
(23)
Conventional PCR Forward primer: 5′-AGCGACTCTGCTGGAAATGAT-3′
Reverse primer: 5′-TGATTAGCTAAGGCATTCCCA-3′
(20)
(Continued)
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Gene/region Method Primers Reference
LMP-2 gene Real-time PCR Forward primer: 5′-AGCTGTAACTGTGGTTTCCATGA-3′
Reverse primer: 5′-GCCCCCTGGCGAARAG-3′
Probe: 6-FAM-CTGCTGCTACTGGCTTTCGTCCTCTGG-TAMRA
(23)
BALF5 gene Real-time PCR Forward primer: 5′-CGGAAGCCCTCTGGACTTC-3′
Reverse primer: 5′-CCCTGTTT ATCCGATGGAATG-3′
Probe: 5′-TGTACACGCACGAGAAATGCGCC-3′
(136)
BamHI-F region Conventional PCR Forward primer: 5′-TCC CAC CTG TTA CCA CAT TC-3′
Reverse primer: 5′- GGC AAT GGG ACG TCT TGT AA-3′
(139)
EBER1 Conventional PCR Forward primer: 5′-TCTGTGGCAGGAGTGGTGGGCCCTGAACAT-3′
Reverse primer: 5′-AGACACCGTCCTCACCACCCGGGACTTGTA-3′
(139)
TABLe 1 | Continued
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decline but continue to be present in a detectable level for life 
Thus, detection of EBNA-1 antibodies indicates past or recover-
ing EBV infection (6, 110). However, VCA-IgG indicates past 
infection more accurately than EBNA-IgG because EBNA-IgG is 
never developed in around 5–10% of EBV infected healthy indi-
viduals, and this percentage is higher in immunocompromised 
patients (102, 111). Usually, antibodies against EBNA are tested by 
standard immunofluorescent assays and enzyme immunoassays. 
However, EBNA enzyme immunoassays may give false-positive 
results (1, 101, 104). The IgM class of EBNA-1 is not usually 
measured, but when detected, it indicates a recent primary infec-
tion, however, it may persist for several months after the primary 
infection, and it can reappear again in the reactivation process 
(101). The EBNA-1 IgM has cross-reactivity with other viruses 
such as CMV and Parvovirus B19, and it may show false negative 
results (112, 113).
The EA is a complex of nonstructural proteins that are expressed 
by EBV infected cells in the lytic phase. EA is composed of two 
components: diffused EA-D and restricted EA-R (114). IgG anti-
bodies against EA are detected transiently in up to 3 months or 
more during infection mononucleosis (111). Usually the humoral 
response is against the D component; however, children under-
going silent EBV seroconversion might also produce antibodies 
to the R component (101, 115). High levels of EA-R antibodies 
have been detected in Burkitt’s lymphoma (101), and can also 
be indicative of reactivation of a latent EBV infection (116). In 
contrast, high titers of EA-D were found to be produced in NPC 
patients (117). Hence, detection of only EA antibodies cannot 
serve as an ultimate diagnosis to identify the EBV condition, 
because high titers are found in different diseases, and in healthy 
individuals as well (118). Usually, EA antibodies appear in the 
acute phase and then declines to undetectable levels. However, 
studies showed that only 60–85% of acute infection patients have 
EA positive results (99, 102) and 20–30% of healthy individuals 
with past EBV infection have detectable levels of EA antibodies 
(99). Because of abovementioned reasons, the diagnostic value of 
these antibodies is still debatable (101). Nevertheless, combining 
EA antibodies testing with other diagnostic tools can be useful 
in the diagnosis.
In general, the EBV infection in immunocompetent patients is 
detected and classified using the previously mentioned antibod-
ies in patients’ sera. However, when results are uninterpretable 
or cannot clearly distinguish the stage of infection, other assays 
can be done to confirm the suspected diagnosis, such as western 
blot, immunoblot, and more commonly, the IgG avidity testing 
(18, 102).
igG AviDiTY ASSAY
Due to the high variability and cross-reactivity in EBV serologi-
cal responses, mainly with the VCA antibodies, more parameters 
are occasionally needed to confirm the infection condition. IgG 
avidity assay is usually employed in combination with other 
serologic markers. This method is based on the principle that 
during the acute phase of infection, the binding strength of 
EBV IgG antibodies to their target antigens is not as high as the 
antibodies binding strength after finishing the acute infection, 
as the antibodies undergo maturation (101, 119). Treating low 
avidity IgG antibodies with urea or chaotropic reagent leads to 
antibodies disassociation. Consequently, the difference in the 
antibodies amount before and after urea treatment is evaluated 
to determine the avidity strength which in turn represents the 
stage of infection and distinguish acute from past infection 
(102, 120). This method was found to be a reliable tool in EBV 
primary infection confirmation in patients with undetectable 
VCA-IgM, as well in the differential diagnosis (18, 120).
MOLeCULAR ASSAYS
Various molecular techniques have been developed and applied 
to detect EBV DNA and to quantify the viral load (68, 121–123). 
In situ hybridization, RNA and protein based assays, detection 
of EBV DNA in blood samples by quantitative real-time PCR 
(qRT-PCR), Southern blotting and Dot blotting have all been 
used in the diagnosis and monitoring of primary EBV infection, 
reactivation, and in EBV-related diseases (68, 124). These meth-
ods aid in the diagnosis, but due to the lack of standardization, 
the difference in sensitivity and specificity from the laboratory to 
laboratory should always be considered (101).
A growing body of evidence indicates the importance of using 
qRT-PCR as a sensitive and reliable method and a complementary 
tool to other serologic markers, in particular, for diagnosis of 
EBV acute infection and EBV silent reactivation (59, 103, 125, 
126). More importantly, this method is very crucial and widely 
used in monitoring the immune status of immunocompromised 
patients as well as in patients at risk of developing EBV-related 
TABLe 2 | Prevalence of Epstein–Barr virus DNA in various samples.
Country Sample type Sample size Seroprevalence (%) Genotype Diagnostic assay used Year Reference
United 
States of 
America
Whole blood 143 42 (29.3) – Real-time quantitative polymerase chain reaction 2012 (133)
Whole blood 92 75 (82) – In-house quantitative real-time polymerase  
chain reaction
2012 (134)
Plasma 116 15 (13)
PMNCs 64 56 (88)
Oral wash: cell pellet
Supernatant
143 66 (46)
61 (42.6)
Whole blood 19 5 (26) – Real-time quantitative polymerase chain reaction 2016 (147)
Whole blood 66 42 (64) – Real-time quantitative polymerase chain reaction 2013 (133)
Whole blood 86 7 (8) – Real-time quantitative polymerase chain reaction 2016 (135)
Colombia Saliva 17 9 (52.9) – In-house Real-time polymerase chain reaction 2016 (148)
Brazil Saliva 100 60 (60) – Nested polymerase chain reaction 2018 (149)
Saliva and fresh tissue 
samples
17 each 64.7
35.3
– Nested polymerase chain reaction 2016 (150)
Scraping samples of the 
tongue lateral border
53 53 (100) Type 1,2 Nested polymerase chain reaction 2008 (151)
Australia Tissue 55 55 (100) Type 1, 2 DNA sequence analysis 2012 (152)
eUROPe
Czech 
Republic
Whole blood 29 19 (66) – Real-time quantitative polymerase chain reaction 2011 (153)
Plasma 29 22 (76)
Poland Fresh frozen tumor tissue 78 Oropharyngeal 
cancer
40 (51.3) – Nested polymerase chain reaction 2016 (154)
Saliva 40 healthy 8 (20)
Saliva 56 22 (39.3) Type 1 Nested polymerase chain reaction 2004 (55)
Sweden Cervical secretions 305 32 (10.5) Real-time quantitative polymerase chain  
reaction
(155)
Germany Saliva 47 14 (30) – Polymerase chain reaction 2017 (156)
Serbia Tissue 80 37 (46.6) Type 1 Nested polymerase chain reaction 2016 (147)
ASiA
Qatar PMNCs 673 354 (52.6) – Real-time quantitative polymerase chain  
reaction
2013 (23)
China PMNCs 859 206 (24) – Polymerase chain reaction and restricted 
fragment length polymorphisms (RFLP)
2017 (137)
Plasma 1,318 69 (5.2) – Real-time polymerase chain reaction 2013 (141)
Saliva 20 20 (100) Type 1,2 Quantitative polymerase chain reaction 2015 (76)
Paraffin-embedded  
tissues
209 146 (69.9) Type 1,2 Quantitative polymerase chain reaction 2014 (157)
India Serum 40 37 (92.5) – Standard phenol chloroform method  
and then polymerase chain reaction
2016 (158)
AFRiCA
Kenyan Purified T-cell fractions  
saliva and breast milk
– – Type 2 – 2017 (159)
Egypt Paraffin-embedded  
samples of breast tissue
84 32 (38) – Nested polymerase chain reaction 2017 (160)
Eritrea Formalin-fixed paraffin-
embedded breast cancer 
tissue
144 40 (27.77) – Polymerase chain reaction 2017 (161)
Sudan – 150 92 (61.3) – Polymerase chain reaction 2015 (162)
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diseases (127–129). However, the threshold value in which medical 
intervention is required, the units of measurement, and the best 
specimen to be used for DNA testing are still questionable and 
not standardized (101). Moreover, there is still no consensus on 
the ideal method for performing qRT-PCR in case of EBV detec-
tion and quantification, and this increases the variability between 
laboratories and between studies (68). Different detection meth-
ods are available commercially. Some commercial primers and 
probes target include LMP-2 gene, BHRF-1 (a transmembrane 
protein), BKRF1 (EBNA-1 gene), BNRF1 (a major tegument 
protein), BXLF1 (thymidine kinase), BZLF1 (ZEBRA), or BALF5 
(viral DNA polymerase) (68, 101) Table 1 summarizes the most 
commonly used primers in the detection of EBV DNA. The unit 
of measurement also varies; it can be reported as copies per DNA 
concentration as copies per microgram of DNA, or copies per 
milliliter, copies per 100,000 white blood cells, and copies per 
11
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positive cell (68, 101, 130). Samples that used in qRT-PCR assays 
are various, including serum, whole blood, tissue biopsy, and 
peripheral blood mononuclear cells (PMNCs). Although there 
is still debate concerning these issues, in general, the choice of 
the specimen to be used is based on the patient’s condition and 
the stage of the disease. Studies on the EBV life cycle showed 
that production of EBV virions during the acute phase of infec-
tion and the degradation of EBV DNA by apoptotic cells, both 
lead to the spread of virions and free or degraded EBV in the 
peripheral blood of the patient, and therefore, this allows for EBV 
DNA detection in patients’ peripheral blood (124, 131, 132). In 
the latent phase of the infection, transformed B lymphocytes 
also travel to the blood (101). Consequently, EBV DNA in acute 
infection can be detected in the serum or in the unfractionated 
blood, as well as in the PMNCs. Table 2 describes the molecular 
prevalence of EBV DNA using different sample types.
The EBV DNA in acutely infected patients can be detected 
within 2 weeks of the onset of symptoms, and it reaches its peak 
of detection during this time (101). Then, after the initiation of 
the immune response, the viral load starts to decrease rapidly 
to low or even undetectable levels in the plasma or serum (125). 
After that, the immune response decreases slowly in the cel-
lular portion of blood, where it remains latent in the memory 
cells for a long time, and thus it can be detected if the sample 
is PMNCs (68, 142). However, it is important to consider the 
individual differences in EBV kinetics between patients as the 
viral load might take up to one year to reach a stable low level in 
some individuals according to immune status and the patient’s 
condition (68, 143). Studies showed that healthy individuals 
carry a stable number of EBV infected cells (81). In a healthy 
carrier, latently infected memory B lymphocytes harbor the 
EBV genome, approximately, per 1 million leukocytes, there 
are 1–50 copies of EBV DNA, while in serum or plasma EBV 
DNA is almost below the limit of detection (68) for the same 
individual. Therefore, the ability to detect EBV DNA in serum 
might serve as a useful indicator for EBV primary infection or 
reactivation. Patients with active infection or with EBV-related 
cancers have been found to have a higher viral load in their 
cell-free blood (68).
Epstein–Barr virus DNA detection in patient’s serum can be 
useful especially in the early stages of the acute infection, and it 
can be even more sensitive than serology and IgG avidity test-
ing as previously reported (125). However, is not necessary to 
performed DNA detection for immunocompetent patients, as 
serology is sufficient unless the result is indeterminate and an 
additional test is needed (144), or when the EBV infection is 
strongly suspected with negative serology results (145). In EBV-
associated diseases, the sample of choice differs based on the type 
of disease. For example, serum can be useful in detecting EBV 
DNA in Hodgkin’s lymphoma patients as the biology of the disease 
includes migration of episomal or apoptotic cells derived EBV 
DNA to the bloodstream. In this specific case, plasma or serum 
samples are desirable for EBV quantification (124). Similarly, 
in NPC, cancer cells proliferate in the tissue and uncommonly 
migrate to the peripheral blood, but cell-free EBV DNA can be 
detected in the peripheral blood using a serum or plasma sample 
(124). In contrast, in PTLD, the disease biology involves blast B 
lymphocytes migration to the bloodstream, accordingly, using 
a PMNC specimen in preferable (124). Furthermore, the viral 
load correlates with the severity of the disease in EBV-associated 
malignancies and lymphoproliferative diseases, and it was found 
to be a useful prognostic marker (142, 146).
CONCLUSiON AND FUTURe DiReCTiONS
Epstein–Barr virus is a highly prevalent virus affecting more 
than 90% of individuals worldwide. Serological diagnosis is 
widely used in investigating the EBV infection, with VCA-IgG 
antibodies detection being the best single serological test to 
indicate previous EBV exposure. Molecular testing is also an 
important diagnostic tool especially in immunocompromised 
patients, where serology results may be confusing and unclear 
due to the incomplete humoral response. However, a combina-
tion of both molecular and serological methods would result in 
early detection of viruses and accurate diagnosis of the infection. 
Despite the wide number of studies concerning EBV detection, 
studies investigating the EBV viremia and genetic variability 
in healthy individuals are still limited, although this virus is 
transfusion transmissible and linked to PTLDs and a wide range 
of other malignancies. Estimates of EBV infection are important 
to give researchers and clinicians accurate data concerning the 
prevalence of the virus, and consequently, improving the safety 
of health practices to eliminate the EBV spread, especially in 
blood banks, and organ transplantation centers where EBV 
constitutes a life-threatening risk to recipients. In this regard, 
although recent reports showed that healthy individuals could 
carry high-risk variants of the LMP-1, which might contribute 
to cancer development, the majority of the published studies 
have investigated the genetic variability of the LMP-1 oncogene 
among cancer patients but not in healthy carriers. For this rea-
son, we believe that understanding EBV molecular epidemiol-
ogy in different populations and identifying the circulating EBV 
strains can be an aspect of crucial importance in view of a global 
preventive approach against all the pathological conditions 
associated with this virus. Finally, due to the lack of adequate 
reports from these areas, we believe further studies should be 
conducted in the Middle East and North Africa regions in order 
to compare the circulating EBV strains with other regions of 
the world.
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